Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years

Vaccine

Volumn 33, Issue 18, 2015, Pages 2189-2195

  Godeaux, Olivier ^a   Izurieta, Patricia ^a   Madariaga, Miguel ^b   Dramé, Mamadou ^c   Li, Ping ^c   Vaughn, David W ^a  

^a GSK   (Belgium)

^b Naples Community Hospital Healthcare System   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

AS03; Bulk antigen; H5N1 vaccine; Pandemic influenza; Stockpile

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; COUGHING; DERMATITIS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG STORAGE; DYSGEUSIA; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMAGGLUTINATION INHIBITION TEST; HEMATOMA; HERNIA; HUMAN; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; NECK PAIN; OPEN STUDY; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; SEROCONVERSION; SHELF LIFE; SHIVERING; SIDE EFFECT; SINUSITIS; SMALL CELL LUNG CANCER; SWEAT GLAND DISEASE; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION; VACCINE STOCKPILING; XEROSIS; ADOLESCENT; BLOOD; CLINICAL TRIAL; HEALTH CARE PLANNING; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); STANDARDS; TIME; VACCINATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; SEROCONVERSION; STRATEGIC STOCKPILE; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84926416689     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.062     Document Type: Article

References (19)

1. World Health Organization Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness 2013, February, [accessed 04.12.13]. http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf.
2. World Health Organization Pandemic influenza vaccine manufacturing process and timeline 2013, [accessed 04.12.13]. http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/index.html.
3. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442(7101):448-452.
4. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008, 8(10):650-658.
5. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9(8):1057-1071.
6. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201(11):1644-1653.
7. Gillard P., Caplanusi A., Knuf M., Roman F., Walravens K., Moris P., et al. An assessment of prime-boost vaccination schedules with AS03A - adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respi Viruses 2013, 7(1):55-65.
8. Food and Drug Administration FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza 2013, November 22, [accessed 04.12.13]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376444.htm.
9. Hehme N., Engelmann H., Kuenzel W., Neumeier E., Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004, 103(1-2):163-171.
10. Kendal A., Pereira M., Skehel J. Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance. 1982, B17-B35. Centers for Disease Control and Prevention and Pan-American Health Organization, Atlanta. A.P. Kendal, M.S. Pereira, J.J. Skehel (Eds.).
11. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
12. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004, 103(1-2):91-95.
13. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines 2007, May, [accessed 04.12.13]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm.
14. European Medicines Agency, European Committee for Proprietary Medicinal Products CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine 2009, September, [accessed 04.12.13]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051739.pdf.
15. Langley J.M., Risi G., Caldwell M., Gilderman L., Berwald B., Fogarty C., et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011, 203(12):1729-1738.
16. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(9587):580-589.
17. World Health Organization Options for the design and financing of an H5N1 vaccine stockpile: key findings and study methodology 2013, [accessed 04.12.03]. http://www.who.int/influenza/preparedness/pandemic/H5N1_Stockpile_Design_Feb2009.pdf.
18. Heijmans S., De Meulemeester M., Reynders P., Giet D., Demanet E., Devresse P.Y., et al. Immunogenicity profile of a 3.75-mug hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011, 203(8):1054-1062.
19. Rumke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26(19):2378-2388.